The company maintains a conservative capital structure with a negligible debt-to-equity ratio of 0.02, supported by a robust $1.4 billion cash position as of 2025Q4.
| Total Current Assets | 5.17B | 5B | 6.73B | 1.8B | 2.15B | 2.19B | 2.22B |
| Cash & Short-Term Investments | 4.3B | 4.89B | 6.54B | 1.68B | 2.06B | 2.13B | 2.19B |
| Cash Only | 1.42B | 2.72B | 6.54B | 1.68B | 2.06B | 2.13B | 2.19B |
| Short-Term Investments | 2.87B | 2.17B | 5.37M | 5.01M | 0 | 0 | 0 |
| Accounts Receivable | 789.84M | 0 | 82.81M | 37.64M | 6.73M | 13.83M | 15.28M |
| Days Sales Outstanding | 34.9K | - | 924 | 435.78 | 44.44 | 212.17 | 82.39 |
| Inventory | 0 | 0 | 35.25M | 2.76M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | 8.05K | 332.16 | - | - | - |
| Other Current Assets | 81.86M | 113.17M | 17.59M | 20.44M | 26.02M | 874K | 2.14M |
| Total Non-Current Assets | 560.66M | 436.88M | 490.65M | 591.02M | 438.61M | 502.7M | 257.81M |
| Property, Plant & Equipment | 92.4M | 101.08M | 65.95M | 92.34M | 86.95M | 77.03M | 73.93M |
| Fixed Asset Turnover | 0.09x | 0.29x | 0.50x | 0.34x | 0.64x | 0.31x | 0.92x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 137.84M | 144.88M | 0 | 0 | 0 |
| Long-Term Investments | 415.88M | 302.94M | 247.75M | 304.32M | 325.83M | 398.47M | 177.22M |
| Other Non-Current Assets | 33.02M | 32.86M | 39.11M | 49.48M | 25.82M | 27.2M | 6.66M |
| Total Assets | 5.73B | 5.44B | 7.22B | 2.39B | 2.59B | 2.69B | 2.48B |
| Asset Turnover | 0.00x | 0.01x | 0.00x | 0.01x | 0.02x | 0.01x | 0.03x |
| Asset Growth % | 5.35% | -24.72% | 202.25% | -7.56% | -3.89% | 8.58% | - |
| Total Current Liabilities | 281.24M | 149.41M | 266.76M | 272.45M | 184.37M | 218.96M | 92.12M |
| Accounts Payable | 18M | 23.69M | 53.23M | 37.83M | 34.58M | 20.55M | 10.31M |
| Days Payables Outstanding | 5.11K | 9.49K | 12.15K | 4.55K | 1.41K | 3.65K | 3.33K |
| Short-Term Debt | 11.15M | 9.84M | 12M | 40.72M | 0 | 12.31M | 7.84M |
| Deferred Revenue (Current) | 0 | 1.17M | 4.17M | 12.44M | 10.15M | 5.92M | 3.62M |
| Other Current Liabilities | 119.08M | 53.93M | 85.94M | 74.84M | 83.98M | 141.42M | 39.74M |
| Current Ratio | 18.37x | 33.47x | 25.24x | 6.60x | 11.64x | 9.99x | 24.09x |
| Quick Ratio | 18.37x | 33.47x | 25.10x | 6.59x | 11.64x | 9.99x | 24.09x |
| Cash Conversion Cycle | - | - | -3.18K | -3.78K | - | - | - |
| Total Non-Current Liabilities | 154.39M | 100.33M | 507.19M | 509.57M | 339.33M | 308.73M | 276.24M |
| Long-Term Debt | 0 | 0 | 430.59M | 375.51M | 210.03M | 170.28M | 108.59M |
| Capital Lease Obligations | 96.29M | 90.33M | 47.27M | 53.48M | 62.47M | 62.38M | 64.45M |
| Deferred Tax Liabilities | 19.36M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 38.74M | 10M | 29.34M | 80.58M | 53.09M | 76.06M | 103.19M |
| Total Liabilities | 435.63M | 249.74M | 773.95M | 782.02M | 523.7M | 527.69M | 368.36M |
| Total Debt | 107.44M | 100.17M | 499.75M | 481.4M | 283.89M | 244.98M | 180.88M |
| Net Debt | -1.32B | -2.62B | -6.04B | -1.2B | -1.78B | -1.89B | -2B |
| Debt / Equity | 0.02x | 0.02x | 0.08x | 0.30x | 0.14x | 0.11x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -23.72x | -28.93x | -130.20x | -318.88x | -72.02x |
| Total Equity | 5.29B | 5.19B | 6.45B | 1.61B | 2.06B | 2.16B | 2.11B |
| Equity Growth % | 2.03% | -19.56% | 301.13% | -22.02% | -4.65% | 2.53% | - |
| Book Value per Share | 7.63 | 7.15 | 7.76 | 2.26 | 3.08 | 3.16 | 3.08 |
| Total Shareholders' Equity | 4.53B | 4.69B | 5.97B | 1.16B | 1.66B | 1.9B | 2.03B |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -501.81M | 116.06M | 576.17M | -3.77B | -2.76B | -1.92B | -1.11B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4.36M | 9.44M | -4.08M | -2.62M | -946K | 1.45M | -2.35M |
| Minority Interest | 765.04M | 499.59M | 479.95M | 449.82M | 404.49M | 264.22M | 76.53M |
Binary Clinical Trial Outcomes
As reported in recent financial filings, Roivant's total assets have contracted from $7.3 billion in 2023Q3 to $5.7 billion in 2025Q4, a trend primarily driven by the strategic monetization of pipeline assets rather than a fundamental degradation of the company's underlying research and development capabilities.
The reduction in total assets appears to be a deliberate outcome of the company's hub-and-spoke model, which prioritizes the recycling of capital through high-value divestitures. Investors should monitor whether this shrinking asset base limits future pipeline optionality or if it simply reflects the successful execution of the firm's asset-arbitrage strategy.
Based on the latest quarterly balance sheet, Roivant maintains a robust liquidity position with $1.4 billion in cash and equivalents, providing a significant buffer against the company's ongoing operational burn and supporting its ability to fund late-stage clinical trials without immediate reliance on dilutive capital markets.
The current ratio of 18.37 suggests an exceptionally high level of short-term solvency, which is atypical for a pre-commercial biotech firm. This liquidity profile appears to be a direct result of past milestone payments and divestitures, granting management the flexibility to pursue aggressive R&D initiatives despite persistent operating deficits.
According to reported figures, Roivant maintains a conservative capital structure with total debt of $107.4 million as of 2025Q4, resulting in a negligible debt-to-equity ratio of 0.02 that underscores the company's reliance on equity-based funding rather than debt to finance its decentralized research operations.
The low leverage profile suggests that the company is not constrained by interest obligations, which is a critical advantage given the inherent volatility of its clinical pipeline. This lack of debt indicates that the firm's primary financial risk remains the clinical success of its assets rather than credit market sensitivity.
As disclosed in recent financial statements, Roivant's equity base has shifted from a peak of $6.1 billion in 2023Q3 to $4.5 billion in 2025Q4, a decline largely attributable to the accumulation of retained losses as the company continues to prioritize heavy R&D investment over near-term profitability.
The transition into negative retained earnings of $501.8 million suggests that the company's historical profitability was heavily reliant on non-recurring divestiture gains. Investors should consider whether the current equity valuation accurately reflects the long-term potential of the remaining pipeline or if it is inflated by past capital recycling events.
Quick answers to the most common questions about buying ROIV stock.
As of 2025, Roivant Sciences Ltd. (ROIV) had total assets of $5.73B including $5.17B in current assets.
Roivant Sciences Ltd. (ROIV) carries total debt of $107.4M, offset by $4.30B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Roivant Sciences Ltd. (ROIV) has total shareholders' equity (book value) of $4.53B ($7.63 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Roivant Sciences Ltd. (ROIV) reported a current ratio of 18.37x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.